Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0J6DQ
|
||||
Former ID |
DNCL002655
|
||||
Drug Name |
Tremelimumab
|
||||
Drug Type |
Monoclonal antibody
|
||||
Company |
AstraZeneca
|
||||
CAS Number |
CAS 745013-59-6
|
||||
Target and Pathway | |||||
Target(s) | Cytotoxic T-lymphocyte protein 4 | Target Info | Modulator | [543700] | |
Pathway Interaction Database | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | ||||
Reactome | CTLA4 inhibitory signaling | ||||
References | |||||
Ref 525318 | ClinicalTrials.gov (NCT02551159) Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN. | ||||
Ref 543152 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8462). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.